Managing Bleeding Risk in Patients with CLL on BTKi Therapy

Opinion
Video

A panel of oncology experts review meta-analysis data evaluating bleeding risk with covalent BTKis, discuss the impact of these data on treatment decision making, and explore strategies in managing BTKi-related bleeding risk.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
      Novel BTK Degrader Shows Activity in CLL/SLL Regardless of Mutation Status
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      More Research Needed to Ascertain Ziftomenib’s Mechanism of Action in AML
      More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
      Bexmarilimab Shows Survival Efficacy in Relapsed/Refractory MDS
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      Related Content
      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

      Russ Conroy
      June 25th 2025
      Article

      The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

      Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
      June 9th 2025
      Podcast

      An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

      Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

      EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management

      Russ Conroy
      June 18th 2025
      Article

      Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

      Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

      Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
      May 5th 2025
      Podcast

      Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

      Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL

      Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL

      Ashley Chan
      June 18th 2025
      Article

      Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.

      Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

      Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

      Jax DiEugenio
      June 17th 2025
      Article

      Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.